Skip to content
10-Q

Quarterly Report

Skye Bioscience, Inc. SKYE

0001516551-25-000042

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 30.98M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $12.8M
Short Term Investments Q1 2025 · Dec 31, 2024 $0
Cash And Equivalents Q1 2025 · Mar 31, 2025 $46.42M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $68.42M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $83.34M
Current Liabilities Q1 2025 · Mar 31, 2025 $5.32M
Current Liabilities Q1 2025 · Dec 31, 2024 $4.34M
Total Liabilities Q1 2025 · Mar 31, 2025 $5.54M
Total Liabilities Q1 2025 · Dec 31, 2024 $4.61M
Current Assets Q1 2025 · Mar 31, 2025 $63.03M
Current Assets Q1 2025 · Dec 31, 2024 $70.83M
Total Assets Q1 2025 · Mar 31, 2025 $64.79M
Total Assets Q1 2025 · Dec 31, 2024 $72.76M
Shares Diluted Q1 2025 · Mar 31, 2024 28M sh
Capex Q1 2025 · Mar 31, 2024 $3.18K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$4.71M
Stockholders Equity Q1 2025 · Mar 31, 2024 $78.88M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$2.13M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.18
Eps Basic Q1 2025 · Mar 31, 2024 −$0.18
Sga Expense Q1 2025 · Mar 31, 2024 $4.21M
Net Income Q1 2025 · Mar 31, 2024 −$5.02M
Operating Income Q1 2025 · Mar 31, 2024 −$6.15M